PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to boost platelets in severe ITP patients
Disease control Not yet recruitingThis study tests a treatment plan for adults with severe immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants will receive steroids and a platelet-boosting drug in the hospital for 14 days, followed by a 10-we…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE4 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 17, 2026 10:39 UTC
-
New hope for ITP patients: drug switch study tests two strategies after treatment failure
Disease control Not yet recruitingThis study looks at 112 people with immune thrombocytopenia (ITP) whose platelets didn't improve with standard-dose rhTPO. After a two-week break, they will either get a double dose of rhTPO or switch to eltrombopag. The goal is to see which approach better raises platelet counts…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo aims to free ITP patients from long-term medication
Disease control Not yet recruitingThis study tests whether combining two drugs—orelabrutinib and romiplostim—can help adults with chronic immune thrombocytopenia (ITP) maintain safe platelet levels and eventually stop other treatments. About 28 participants who have already tried at least one standard therapy wil…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated May 15, 2026 11:53 UTC